Ann: Appendix 4C - Quarterly, page-22

I excerpt some contents from quarterly report:

Products:

l CelGro® Platform Medical Device- The global addressable market for CelGro® is in excessof US$2.6bn and growing.

1. Bone regeneration (US$0.6bn) - Achieved EU regulatory approval and waitingfor approval from TGA in Q3 2019 and FDA in Y2020

2. Tendon & Soft tissue regeneration (US$0.9bn) – soft tissue Achieved EU regulatory approval andwaiting for approval from TGA in Q3 2019 and FDA in Y2020

3. Nerve regeneration (US$1.1 bn) - further clinical update planned for 3Q CY2019

l Ortho-ATI®: (a world-leading breakthrough in regenerative medicine) - estimatedto be worth >US$7.7bn and growing.

- clinical trialof Ortho-ATI® versus corticosteroid injection by 3Q CY2019,progressing the collaboration with Johnson& Johnso.

l Ortho-ACI®: aim toregenerate damaged tendon and cartilage tissue

Have anybody noticed that they only mentioned in Y2020 for CelGro soft tissue regeneration? they wrote in Q1 Y2020 in previous ann, does that mean it will be delayed?

BTW, the company's yearly net operating cash flow was about 4.1M, while the revenue was only 1M, how far they can go if there is not another CR?